Publication Name	World Journal of Gastroenterology
Manuscript ID	9336
Country	China

Received	2014-02-09 14:50
Peer-Review Started	2014-02-10 12:02
To Make the First Decision	2014-02-28 15:58
Return for Revision	2014-03-13 10:09
Revised	2014-04-11 14:40
Second Decision	2014-05-14 09:26
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-05-14 09:28
Articles in Press	2014-05-23 10:42
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-05-20 18:29
Typeset the Manuscript	2014-08-15 10:20
Publish the Manuscript Online	2014-08-29 11:57

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Observational Study
Article Title	Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients
Manuscript Source	Unsolicited Manuscript
All Author List	Xin Zhang, Shu-Zhen Wang, Jun-Fu Zheng, Wen-Min Zhao, Peng Li, Chun-Lei Fan, Bing Li, Pei-Ling Dong, Lei Li and Hui-Guo Ding
Funding Agency and Grant Number	Funding Agency Grant Number Program of Beijing Science and Technology Commission D131100005313004 Beijing High-Level Talent Academic Leader/Personnel Training Programs awarded 2011-2-19 (to Ding HG) Beijing High-Level Talent Academic Leader/Personnel Training Programs awarded 2013-3-072 (to Li B) Beijing High-Level Talent Academic Leader/Personnel Training Programs awarded 2013-3-073 (to Li L)
Corresponding Author	Correspondence to: Hui-Guo Ding, MD, PhD, Director, Department of Gastroenterology and Hepatology, Beijing You’an Hospital, Affiliated with Capital Medical University, Fengtai District, Beijing 100069, China. dinghuiguo@medmail.com.cn
Key Words	Tolvaptan; Refractory ascites; Hyponatremia; Decompensation; Liver cirrhosis
Core Tip	This study showed that tolvaptan, a new aquaretic drug, is an effective and safe potential treatment for refractory ascites in patients with decompensated liver cirrhosis, especially in patients with further complications, such as hepatorenal syndrome and/or hepatocellular carcinoma. Tolvaptan significantly increased the serum sodium levels in patients with hyponatremia.
Publish Date	2014-08-29 11:57
Citation	Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol 2014; 20(32): 11400-11405
URL	http://www.wjgnet.com/1007-9327/full/v20/i32/11400.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i32.11400

Full Article (PDF)	WJG-20-11400.pdf
Full Article (Word)	WJG-20-11400.doc
Manuscript File	9336-Review.docx
Answering Reviewers	9336-Answering reviewers.pdf
Copyright License Agreement	9336-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	9336-Language certificate.pdf
Peer-review Report	9336-Peer reviews.pdf
Scientific Editor Work List	9336-Scientific editor work list.pdf